Aptevo Therapeutics Inc. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
Aptevo Therapeutics Inc. (APVO) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $97.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-08-14
- Aptevo Therapeutics Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2026-06-30 was $0.00.
- Aptevo Therapeutics Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2026-03-31 was $97.00K.
- Aptevo Therapeutics Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-12-31 was $92.00K.
- Aptevo Therapeutics Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-09-30 was $1.48M.
- Aptevo Therapeutics Inc. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2025 was $1.57M.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $97.00K 10-Q · filed 2026-08-14 | $189.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $97.00K 10-Q · filed 2026-05-13 | $189.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.67M derived: sum of 3 quarters · filed 2026-05-13 | $1.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.57M derived: sum of 2 quarters · filed 2026-03-26 | $1.57M derived: sum of 3 quarters · filed 2026-08-14 | $1.57M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.48M 10-Q · filed 2025-11-06 | $1.48M derived: sum of 2 quarters · filed 2026-08-14 | $1.48M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |